cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.6084/m9.figshare.8153312.v1
title: DEM_P16_007228_P15_007017

description: This is a CTX DEM made from images P15_007017_1969_XI_16N329W and P16_007228_1973_XI_17N329W<br>
DOI: 10.6084/m9.figshare.8153285
title: DEM_P16_007228_P15_007017

description: This is a CTX DEM made from images P15_007017_1969_XI_16N329W and P16_007228_1973_XI_17N329W
DOI: 10.6084/m9.figshare.8153285.v1
title: DEM_P16_007228_P15_007017

description: This is a CTX DEM made from images P15_007017_1969_XI_16N329W and P16_007228_1973_XI_17N329W
DOI: 10.6084/m9.figshare.8153258
title: DEM_P18_008139_P22_009576

description: This is a CTX DEM made from images P22_009576_1903_XN_10N004W and P18_008139_1900_XN_10N004W
DOI: 10.6084/m9.figshare.8153258.v1
title: DEM_P18_008139_P22_009576

description: This is a CTX DEM made from images P22_009576_1903_XN_10N004W and P18_008139_1900_XN_10N004W
DOI: 10.6084/m9.figshare.8153252
title: DEM_D06_029421_D06_029487

description: This is a CTX DEM made from images D06_029421_1841_XI_04N349W and D06_029487_1841_XI_04N349W.
DOI: 10.6084/m9.figshare.8153252.v1
title: DEM_D06_029421_D06_029487

description: This is a CTX DEM made from images D06_029421_1841_XI_04N349W and D06_029487_1841_XI_04N349W.
DOI: 10.6084/m9.figshare.8153234
title: DEM_038428_047461

description: This is a HiRISE DEM made from images ESP_047461_1880 and ESP_038428_1880.
DOI: 10.6084/m9.figshare.8153234.v1
title: DEM_038428_047461

description: This is a HiRISE DEM made from images ESP_047461_1880 and ESP_038428_1880.
DOI: 10.6084/m9.figshare.8153195
title: data-sharing_tomographic_US.xlsx

description: dataset pilot study tomographic US
DOI: 10.6084/m9.figshare.8153195.v1
title: data-sharing_tomographic_US.xlsx

description: dataset pilot study tomographic US
DOI: 10.6084/m9.figshare.8153039
title: <i>Bacopa monnieri</i> inhibit hen egg white lysozyme fibrillation and help in retaining its activity at acidic condition

description: Inhibiting protein misfolding and aggregation is crucial for the treatment of several amyloidoses. Though various types of synthetic drugs are being explored as therapeutic agents, herbal extracts are better alternative owing to their natural origin, higher bioavailability and improved biosafety characteristics. In the present study, we demonstrate that night long (∼12 hr) preincubation of hen egg white lysozyme (HEWL) with <i>Bacopa monnieri</i> (brahmi) at neutral pH, impede the aggregation and fibrillation of protein at pH 2.0. Employing different biophysical techniques such as static and dynamic light scattering, Thioflavin T (ThT) assay, sedimentation assay and atomic force microscopy (AFM), we show that brahmi inhibit the HEWL aggregation in concentration dependent manner. 8-anilino-1-naphthalene sulfonate (ANS) fluorescence reveals that brahmi masks the exposure of hydrophobic domain of lysozyme. Significant recovery of enzymatic activity of HEWL in the presence of brahmi at pH 2.0 is salient feature of this work. Nearly 90% recovery of catalytic activity of lysozyme after 216 hr (9 days) of incubation indicate that interaction of HEWL-brahmi stabilizes the native structure of protein thus enhancing the activation energy barrier for protein misfolding and subsequent aggregation. Our findings show that brahmi could be promising alternative for the therapies of several protein misfolding disorders. Communicated by Ramaswamy H. Sarma
DOI: 10.6084/m9.figshare.8153039.v1
title: <i>Bacopa monnieri</i> inhibit hen egg white lysozyme fibrillation and help in retaining its activity at acidic condition

description: Inhibiting protein misfolding and aggregation is crucial for the treatment of several amyloidoses. Though various types of synthetic drugs are being explored as therapeutic agents, herbal extracts are better alternative owing to their natural origin, higher bioavailability and improved biosafety characteristics. In the present study, we demonstrate that night long (∼12 hr) preincubation of hen egg white lysozyme (HEWL) with <i>Bacopa monnieri</i> (brahmi) at neutral pH, impede the aggregation and fibrillation of protein at pH 2.0. Employing different biophysical techniques such as static and dynamic light scattering, Thioflavin T (ThT) assay, sedimentation assay and atomic force microscopy (AFM), we show that brahmi inhibit the HEWL aggregation in concentration dependent manner. 8-anilino-1-naphthalene sulfonate (ANS) fluorescence reveals that brahmi masks the exposure of hydrophobic domain of lysozyme. Significant recovery of enzymatic activity of HEWL in the presence of brahmi at pH 2.0 is salient feature of this work. Nearly 90% recovery of catalytic activity of lysozyme after 216 hr (9 days) of incubation indicate that interaction of HEWL-brahmi stabilizes the native structure of protein thus enhancing the activation energy barrier for protein misfolding and subsequent aggregation. Our findings show that brahmi could be promising alternative for the therapies of several protein misfolding disorders. Communicated by Ramaswamy H. Sarma
DOI: 10.6084/m9.figshare.12871313
title: Supplementary Material for: Post-Marketing Safety Concerns with Esketamine: A Disproportionality Analysis of Spontaneous Reports Submitted to the FDA Adverse Event Reporting System

description: <b><i>Introduction:</i></b> Esketamine nasal spray received approval for treatment-resistant depression in March 2019. <b><i>Objective:</i></b> Using the FDA Adverse Event Reporting System (FAERS) database (March 2019–March 2020), we analysed esketamine-related adverse events (AEs) to detect and characterize relevant safety signals. <b><i>Methods:</i></b> We used the consolidated case/non-case approach to estimate the reporting odds ratio (ROR) and information component (IC) with relevant confidence intervals (95% CI) for esketamine-related AEs with ≥4 counts. Comparisons between serious and non-serious AEs were performed using non-parametric tests. <b><i>Results:</i></b> The FAERS database contained 962 cases of esketamine-related AEs, with signals detected for several AEs, such as dissociation (ROR = 1,612.64, 95% CI = 1,354.63, 1,919.79; IC = 8.19, 95% CI = 7.96, 8.35), sedation (ROR = 238.46, 95% CI = 202.98, 280.15; IC = 7, 95% CI = 6.75, 7.18), feeling drunk (ROR = 96.17, 95% CI = 61.42, 150.57; IC = 4.84, 95% CI = 4.09, 5.36), suicidal ideation (ROR = 24.03, 95% CI = 18.72, 30.84; IC = 4.31, 95% CI = 3.9, 4.61), and completed suicide (ROR = 5.75, 95% CI = 3.18, 10.41; IC = 2.25, 95% CI = 1.23, 2.94). Signals for suicidal and self-injurious ideation, but not suicide attempt and completed suicide, remained when comparing esketamine to venlafaxine. Females and patients receiving antidepressant polypharmacy, co-medication with mood stabilizers, antipsychotics, benzodiazepines, or somatic medications were more likely to suffer from serious versus non-serious AEs (χ<sup>2</sup> = 125.29, <i>p</i> &lt; 0.001, χ<sup>2</sup> = 9.08, <i>p</i> = 0.003, χ<sup>2</sup> = 8.14, <i>p</i> = 0.004, χ<sup>2</sup> = 19.48, <i>p</i> &lt; 0.001, χ<sup>2</sup> = 25.62, <i>p</i> &lt; 0.001, and χ<sup>2</sup> = 16.79, <i>p</i> &lt; 0.001, respectively). <b><i>Conclusions:</i></b> Esketamine may carry a clear potential for serious AEs, which deserves urgent clarification by means of further prospective studies.
DOI: 10.7910/dvn/cwglpg/alivgs
title: replication files.zip

description: :unav
DOI: 10.25829/idiv.1806-40-3009
title: Leipzig Catalogue of Vascular Plants (LCVP) and R Package to Query Data

description: The Leipzig Catalogue of Vascular Plants (LCVP) is as far as we know the most updated and resolved list of plant names and their synonyms of all known vascular plant species on this planet.
DOI: 10.6084/m9.figshare.8152943
title: Table_2_data.csv

description: Data from Table 2 published in: Kay, W. P., Naumann, D. S., Bowen, H. J., Withers, S., Evans, B. J., Wilson, R. P., Stringell, T. B., Bull, J. C., Hopkins, P., Borger, L. Minimising the impact of biologging devices: Using Computational Fluid Dynamics for optimising tag design and positioning, <i>Methods in Ecology and Evolution </i>(Accepted). <br>Data are results from computational fluid dynamics simulations. Please refer to publication for details.<br><br>Research funding provided to WPK from the Welsh Government’s European Social Fund (ESF), Natural Resources Wales (NRW) and SEACAMS2. The authors declare no conflict of interest.<br><br>For any queries please contact william.p.kay@swansea.ac.uk
DOI: 10.6084/m9.figshare.8152943.v1
title: Table_2_data.csv

description: Data from Table 2 published in: Kay, W. P., Naumann, D. S., Bowen, H. J., Withers, S., Evans, B. J., Wilson, R. P., Stringell, T. B., Bull, J. C., Hopkins, P., Borger, L. Minimising the impact of biologging devices: Using Computational Fluid Dynamics for optimising tag design and positioning, <i>Methods in Ecology and Evolution </i>(Accepted). <br>Data are results from computational fluid dynamics simulations. Please refer to publication for details.<br><br>Research funding provided to WPK from the Welsh Government’s European Social Fund (ESF), Natural Resources Wales (NRW) and SEACAMS2. The authors declare no conflict of interest.<br><br>For any queries please contact william.p.kay@swansea.ac.uk
DOI: 10.6084/m9.figshare.8152922
title: Soil fungal communities Gutianshan (GTS)

description: Sequence information (18S for AMF and ITS1 for fungi) from soil samples collected in Gutianshan FDP (GTS).<br>This is the data repository for the soil fungal communities in Gutuansan (GTS) project.<br>-----------------File description------------------ sampled_tree_INFO.csv --&gt; Metadata associated with each sample including sample code,species code, tree tag, tree coordinates and dbh(cm).<br>- OTU_table_and_representative_OTU_sequences for ITS1.csv --&gt; OTU tables and representative OTU sequences for ITS1 based fungal community.<br>- OTU_table_and_representative_OTU_sequences for 18S.csv --&gt; OTU tables and representative OTU sequences for 18S based AM fungal community.
DOI: 10.6084/m9.figshare.8152922.v1
title: Soil fungal communities Gutianshan (GTS)

description: Sequence information (18S for AMF and ITS1 for fungi) from soil samples collected in Gutianshan FDP (GTS).<br>This is the data repository for the soil fungal communities in Gutuansan (GTS) project.<br>-----------------File description------------------ sampled_tree_INFO.csv --&gt; Metadata associated with each sample including sample code,species code, tree tag, tree coordinates and dbh(cm).<br>- OTU_table_and_representative_OTU_sequences for ITS1.csv --&gt; OTU tables and representative OTU sequences for ITS1 based fungal community.<br>- OTU_table_and_representative_OTU_sequences for 18S.csv --&gt; OTU tables and representative OTU sequences for 18S based AM fungal community.
DOI: 10.6084/m9.figshare.8152889
title: Real-world incidence of inflammatory bowel disease among patients with other chronic inflammatory diseases treated with interleukin-17a or phosphodiesterase 4 inhibitors

description: <b>Objectives:</b> (1) To assess the real-world incidence of inflammatory bowel disease (IBD) in patients with or without other chronic inflammatory diseases (CIDs), and (2) to understand whether IBD incidence differs in CID patients receiving interleukin-17a signaling antagonists (anti-IL-17a) or phosphodiesterase 4 inhibitors (PDE4i) versus patients using a biologic not indicated for IBD or biologic-naïve patients. <b>Methods:</b> The MarketScan Research Databases (January 2010–July 2017) were used. A CID population was created from patients with ankylosing spondylitis, psoriatic arthritis, psoriasis or rheumatoid arthritis (RA). The CID population was stratified into different cohorts based on the baseline treatments received: (1) anti-IL-17a, (2) PDE4i, (3) biologic-naïve, and (4) non-IBD-indicated biologic (i.e. biologics not indicated for the treatment of IBD and excluding anti-IL-17a and PDE4i); a non-CID cohort was also created. The 1 year incidence rate (IR) of IBD was compared between cohorts using a logistic regression model adjusting for baseline characteristics. <b>Results:</b> CID cohorts included older patients than the non-CID cohort (mean age range: 48.4–54.4 versus 46.3 years). The 1 year IR of IBD was 1.41% in the anti-IL-17a cohort (<i>N</i> = 355), 0.68% in the PDE4i cohort (<i>N</i> = 2195), 0.47% in the biologic-naïve cohort (<i>N</i> = 424,767), 0.51% in the non-IBD-indicated biologic cohort (<i>N</i> = 56,317) cohort and 0.25% in the non-CID cohort (<i>N</i> = 1,008,436). After 1 year of follow-up, the odds of having IBD were 2.85 (<i>p</i> = .0213) and 1.42 (<i>p</i> = .1891) times higher in the anti-IL-17a and PDE4i cohorts, respectively, compared to the biologic-naïve cohort, and 2.86 (<i>p</i> = .0253) and 1.21 (<i>p</i> = .4978) times higher compared to the non-IBD-indicated biologic cohort. Similar results were observed in sensitivity analyses where patients with RA only were excluded (since anti-IL-17a and PDE4i agents are not indicated for RA). <b>Conclusions:</b> Anti-IL-17a treatment was associated with a nearly three-fold higher risk of IBD in CID patients. Treatment decisions for patients with CIDs should take into account the risk of developing of IBD.
DOI: 10.6084/m9.figshare.8152889.v2
title: Real-world incidence of inflammatory bowel disease among patients with other chronic inflammatory diseases treated with interleukin-17a or phosphodiesterase 4 inhibitors

description: <b>Objectives:</b> (1) To assess the real-world incidence of inflammatory bowel disease (IBD) in patients with or without other chronic inflammatory diseases (CIDs), and (2) to understand whether IBD incidence differs in CID patients receiving interleukin-17a signaling antagonists (anti-IL-17a) or phosphodiesterase 4 inhibitors (PDE4i) versus patients using a biologic not indicated for IBD or biologic-naïve patients. <b>Methods:</b> The MarketScan Research Databases (January 2010–July 2017) were used. A CID population was created from patients with ankylosing spondylitis, psoriatic arthritis, psoriasis or rheumatoid arthritis (RA). The CID population was stratified into different cohorts based on the baseline treatments received: (1) anti-IL-17a, (2) PDE4i, (3) biologic-naïve, and (4) non-IBD-indicated biologic (i.e. biologics not indicated for the treatment of IBD and excluding anti-IL-17a and PDE4i); a non-CID cohort was also created. The 1 year incidence rate (IR) of IBD was compared between cohorts using a logistic regression model adjusting for baseline characteristics. <b>Results:</b> CID cohorts included older patients than the non-CID cohort (mean age range: 48.4–54.4 versus 46.3 years). The 1 year IR of IBD was 1.41% in the anti-IL-17a cohort (<i>N</i> = 355), 0.68% in the PDE4i cohort (<i>N</i> = 2195), 0.47% in the biologic-naïve cohort (<i>N</i> = 424,767), 0.51% in the non-IBD-indicated biologic cohort (<i>N</i> = 56,317) cohort and 0.25% in the non-CID cohort (<i>N</i> = 1,008,436). After 1 year of follow-up, the odds of having IBD were 2.85 (<i>p</i> = .0213) and 1.42 (<i>p</i> = .1891) times higher in the anti-IL-17a and PDE4i cohorts, respectively, compared to the biologic-naïve cohort, and 2.86 (<i>p</i> = .0253) and 1.21 (<i>p</i> = .4978) times higher compared to the non-IBD-indicated biologic cohort. Similar results were observed in sensitivity analyses where patients with RA only were excluded (since anti-IL-17a and PDE4i agents are not indicated for RA). <b>Conclusions:</b> Anti-IL-17a treatment was associated with a nearly three-fold higher risk of IBD in CID patients. Treatment decisions for patients with CIDs should take into account the risk of developing of IBD.
DOI: 10.6084/m9.figshare.8152889.v1
title: Real-world incidence of inflammatory bowel disease among patients with other chronic inflammatory diseases treated with interleukin-17a or phosphodiesterase 4 inhibitors

description: <b>Objectives:</b> (1) To assess the real-world incidence of inflammatory bowel disease (IBD) in patients with or without other chronic inflammatory diseases (CIDs), and (2) to understand whether IBD incidence differs in CID patients receiving IL-17a signaling antagonists (anti-IL-17a) or phosphodiesterase 4 inhibitors (PDE4i) versus patients using a biologic not indicated for IBD or biologic-naïve patients. <b>Methods:</b> The MarketScan® Research Databases (1/2010-7/2017) were used. A CID population was created from patients with ankylosing spondylitis, psoriatic arthritis, psoriasis, or rheumatoid arthritis (RA). The CID population was stratified into different cohorts based on the baseline treatments received: (1) IL-17a, (2) PDE4i, (3) biologic-naïve, (4) and non-IBD-indicated biologic (i.e., biologics not indicated for the treatment of IBD excluding anti-IL-17a and PDE4i); a non-CID cohort was also created. The one-year incidence rate (IR) of IBD was compared between cohorts using a logistic regression model adjusting for baseline characteristics. <b>Results:</b> CID cohorts included older patients than the non-CID cohort (mean age range: 48.4-54.4 versus 46.3 years). The one-year IR of IBD was 1.41% in the IL-17a cohort (N = 355), 0.68% in the PDE4i cohort (N = 2,195), 0.47% in the biologic-naïve cohort (N = 424,767), 0.51% in the non-IBD-indicated biologic cohort (N = 56,317) cohort, and 0.25% in the non-CID cohort (N = 1,008,436). After one year of follow-up, the odds of having IBD were 2.85 (<i>P</i> = 0.0213) and 1.42 (<i>P</i> = 0.1891) times higher in the IL-17a and PDE4i cohorts, respectively, compared to the biologic-naïve cohort, and 2.86 (<i>P</i> = 0.0253) and 1.21 (<i>P</i> = 0.4978) times higher compared to the non-IBD-indicated biologic cohort. Similar results were observed in sensitivity analyses where patients with RA only were excluded (since anti-IL-17a and PDE4i agents are not indicated for RA). <b>Conclusions:</b> Anti-IL-17a treatment was associated with a nearly 3-fold higher risk of IBD in CID patients. Treatment decisions for patients with CIDs should take into account the risk of developing of IBD.
DOI: 10.6084/m9.figshare.8152868
title: A single male auditory response test to quantify auditory behavioral responses in <i>Drosophila melanogaster</i>

description: Many animals utilize auditory signals to communicate with conspecific individuals. During courtship, males of the fruit fly <i>Drosophila melanogaster</i> and related species produce a courtship song comprised of sine and pulse songs by vibrating their wings. The pulse song increases female receptivity and male courtship activity, indicating that it functions as a sexual signal. One song parameter, interpulse interval (IPI), varies among closely related species. In <i>D. melanogaster</i>, a song with a conspecific IPI induces a stronger behavioral response than heterospecific songs, indicating the ability of the flies to discriminate conspecific IPI. Traditionally, the fly’s response to the song is measured under grouped conditions, in which the effect of sensory modalities other than audition cannot be excluded. Here, to quantify the individual ability to discriminate a conspecific song, we systematically analyzed the auditory response of single male flies to sound with various parameters. Moreover, we applied this method, termed SMART (Single Male Auditory Response Test), to two sister species for potential application in a comparative approach. By quantifying the locomotor activity of single <i>D. melanogaster</i> males during sound exposure, we detected increased locomotor activity in response to pulse songs, but not to white noise or pure tone. The conspecific song evoked stronger response than the heterospecific songs, and ablation of their antennal receivers severely suppressed the locomotor increase. A pulse song with a small IPI variation evoked a continuous response, while the response to songs with highly variable IPIs tends to be rapidly decayed. This provides the first evidence that fruit flies discriminate IPI variations, which possibly inform the age and social contexts of the singer. Sister species, <i>D. sechellia</i>, exhibited a locomotor response to pulse song, while <i>D. simulans</i> exhibited no behavioral response. This suggests that auditory and other stimuli that elicit this behavioral response are diversified among <i>Drosophila</i> species.
DOI: 10.6084/m9.figshare.8152868.v1
title: A single male auditory response test to quantify auditory behavioral responses in <i>Drosophila melanogaster</i>

description: Many animals utilize auditory signals to communicate with conspecific individuals. During courtship, males of the fruit fly <i>Drosophila melanogaster</i> and related species produce a courtship song comprised of sine and pulse songs by vibrating their wings. The pulse song increases female receptivity and male courtship activity, indicating that it functions as a sexual signal. One song parameter, interpulse interval (IPI), varies among closely related species. In <i>D. melanogaster</i>, a song with a conspecific IPI induces a stronger behavioral response than heterospecific songs, indicating the ability of the flies to discriminate conspecific IPI. Traditionally, the fly’s response to the song is measured under grouped conditions, in which the effect of sensory modalities other than audition cannot be excluded. Here, to quantify the individual ability to discriminate a conspecific song, we systematically analyzed the auditory response of single male flies to sound with various parameters. Moreover, we applied this method, termed SMART (Single Male Auditory Response Test), to two sister species for potential application in a comparative approach. By quantifying the locomotor activity of single <i>D. melanogaster</i> males during sound exposure, we detected increased locomotor activity in response to pulse songs, but not to white noise or pure tone. The conspecific song evoked stronger response than the heterospecific songs, and ablation of their antennal receivers severely suppressed the locomotor increase. A pulse song with a small IPI variation evoked a continuous response, while the response to songs with highly variable IPIs tends to be rapidly decayed. This provides the first evidence that fruit flies discriminate IPI variations, which possibly inform the age and social contexts of the singer. Sister species, <i>D. sechellia</i>, exhibited a locomotor response to pulse song, while <i>D. simulans</i> exhibited no behavioral response. This suggests that auditory and other stimuli that elicit this behavioral response are diversified among <i>Drosophila</i> species.